Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure

Christopher M. O'Connor, Paul A. Gurbel, Victor L. Serebruany

Research output: Contribution to journalArticle

Abstract

P-selectin is an important marker of platelet activation and may be up- regulated in patients with congestive heart failure (CHF). We sought to prospectively compare simultaneously determined platelet and soluble P- selectin in patients with CHF and in healthy controls. Matched soluble levels by enzyme-linked immmunosorbent assay, and platelet-bound expression by whole blood flow cytometry of P-selectin were measured in 22 patients with CHF and compared with 14 healthy controls. Twelve patients were aspirin free and 10 patients were taking aspirin (81 to 500 mg/day). Patients with CHF had significantly elevated soluble P-selectin (186.6 ± 82.7 ng/ml, p = 0.017) and more than twofold increased expression of platelet-bound P-selectin (9.58 ± 7.16% of positive platelets, p = 0.021) compared with the P-selectin profile (102.6 ± 29.0 ng/ml of plasma, and 4.06 ± 1.21% of positive platelets, respectively) in controls. Aspirin therapy did not affect the P- selectin profile in patients with CHF. Despite antecedent aspirin therapy and interindividual variability of the P-selectin profile, soluble and platelet P-selectin were elevated in most patients with severe CHF, suggesting persistent platelet activation.

Original languageEnglish (US)
Pages (from-to)1345-1349
Number of pages5
JournalThe American Journal of Cardiology
Volume83
Issue number9
DOIs
StatePublished - May 1 1999

Fingerprint

P-Selectin
Blood Platelets
Heart Failure
Aspirin
Platelet Activation
Flow Cytometry

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. / O'Connor, Christopher M.; Gurbel, Paul A.; Serebruany, Victor L.

In: The American Journal of Cardiology, Vol. 83, No. 9, 01.05.1999, p. 1345-1349.

Research output: Contribution to journalArticle

O'Connor, Christopher M. ; Gurbel, Paul A. ; Serebruany, Victor L. / Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. In: The American Journal of Cardiology. 1999 ; Vol. 83, No. 9. pp. 1345-1349.
@article{46f93d768d504c10903ff523ab9f009e,
title = "Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure",
abstract = "P-selectin is an important marker of platelet activation and may be up- regulated in patients with congestive heart failure (CHF). We sought to prospectively compare simultaneously determined platelet and soluble P- selectin in patients with CHF and in healthy controls. Matched soluble levels by enzyme-linked immmunosorbent assay, and platelet-bound expression by whole blood flow cytometry of P-selectin were measured in 22 patients with CHF and compared with 14 healthy controls. Twelve patients were aspirin free and 10 patients were taking aspirin (81 to 500 mg/day). Patients with CHF had significantly elevated soluble P-selectin (186.6 ± 82.7 ng/ml, p = 0.017) and more than twofold increased expression of platelet-bound P-selectin (9.58 ± 7.16{\%} of positive platelets, p = 0.021) compared with the P-selectin profile (102.6 ± 29.0 ng/ml of plasma, and 4.06 ± 1.21{\%} of positive platelets, respectively) in controls. Aspirin therapy did not affect the P- selectin profile in patients with CHF. Despite antecedent aspirin therapy and interindividual variability of the P-selectin profile, soluble and platelet P-selectin were elevated in most patients with severe CHF, suggesting persistent platelet activation.",
author = "O'Connor, {Christopher M.} and Gurbel, {Paul A.} and Serebruany, {Victor L.}",
year = "1999",
month = "5",
day = "1",
doi = "10.1016/S0002-9149(99)00098-3",
language = "English (US)",
volume = "83",
pages = "1345--1349",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure

AU - O'Connor, Christopher M.

AU - Gurbel, Paul A.

AU - Serebruany, Victor L.

PY - 1999/5/1

Y1 - 1999/5/1

N2 - P-selectin is an important marker of platelet activation and may be up- regulated in patients with congestive heart failure (CHF). We sought to prospectively compare simultaneously determined platelet and soluble P- selectin in patients with CHF and in healthy controls. Matched soluble levels by enzyme-linked immmunosorbent assay, and platelet-bound expression by whole blood flow cytometry of P-selectin were measured in 22 patients with CHF and compared with 14 healthy controls. Twelve patients were aspirin free and 10 patients were taking aspirin (81 to 500 mg/day). Patients with CHF had significantly elevated soluble P-selectin (186.6 ± 82.7 ng/ml, p = 0.017) and more than twofold increased expression of platelet-bound P-selectin (9.58 ± 7.16% of positive platelets, p = 0.021) compared with the P-selectin profile (102.6 ± 29.0 ng/ml of plasma, and 4.06 ± 1.21% of positive platelets, respectively) in controls. Aspirin therapy did not affect the P- selectin profile in patients with CHF. Despite antecedent aspirin therapy and interindividual variability of the P-selectin profile, soluble and platelet P-selectin were elevated in most patients with severe CHF, suggesting persistent platelet activation.

AB - P-selectin is an important marker of platelet activation and may be up- regulated in patients with congestive heart failure (CHF). We sought to prospectively compare simultaneously determined platelet and soluble P- selectin in patients with CHF and in healthy controls. Matched soluble levels by enzyme-linked immmunosorbent assay, and platelet-bound expression by whole blood flow cytometry of P-selectin were measured in 22 patients with CHF and compared with 14 healthy controls. Twelve patients were aspirin free and 10 patients were taking aspirin (81 to 500 mg/day). Patients with CHF had significantly elevated soluble P-selectin (186.6 ± 82.7 ng/ml, p = 0.017) and more than twofold increased expression of platelet-bound P-selectin (9.58 ± 7.16% of positive platelets, p = 0.021) compared with the P-selectin profile (102.6 ± 29.0 ng/ml of plasma, and 4.06 ± 1.21% of positive platelets, respectively) in controls. Aspirin therapy did not affect the P- selectin profile in patients with CHF. Despite antecedent aspirin therapy and interindividual variability of the P-selectin profile, soluble and platelet P-selectin were elevated in most patients with severe CHF, suggesting persistent platelet activation.

UR - http://www.scopus.com/inward/record.url?scp=0033135060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033135060&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(99)00098-3

DO - 10.1016/S0002-9149(99)00098-3

M3 - Article

C2 - 10235093

AN - SCOPUS:0033135060

VL - 83

SP - 1345

EP - 1349

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -